Anavex Life Sciences (NASDAQ:AVXL) has initiated a long-term extension study, ATTENTION-AD, for patients with early Alzheimer’s disease treated with ANAVEX 2-73 (blarcamesine).
It will be conducted in parallel with the Phase 2b/3 ANAVEX2-73-AD-004 trial.
https://seekingalpha.com/news/3504656-anavex-launches-anavex-2minus-73-extension-study-alzheimer-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.